Version 2 2020-09-04, 15:18Version 2 2020-09-04, 15:18
Version 1 2020-06-15, 21:40Version 1 2020-06-15, 21:40
figure
posted on 2020-09-04, 15:18authored byAda AdminAda Admin, Kung-Hsien Ho, Xiaodun Yang, Anna B. Osipovich, Over Cabrera, Mansuo L. Hayashi, Mark A. Magnuson, Guoqiang Gu, Irina Kaverina
The microtubule
cytoskeleton of pancreatic islet β-cells regulates glucose-stimulated insulin
secretion (GSIS). We have reported that the microtubule-mediated movement of
insulin vesicles away from the plasma membrane limits insulin secretion. High
glucose-induced remodeling of microtubule network facilitates robust GSIS. This
remodeling involves disassembly of old microtubules and nucleation of new
microtubules. Here, we examine the mechanisms whereby glucose stimulation
decreases microtubule lifetimes in β-cells. Using real-time imaging of
photoconverted microtubules, we demonstrate that high levels of glucose induce
rapid microtubule disassembly preferentially in the periphery of individual
β-cells, and this process is mediated by the phosphorylation of
microtubule-associated protein tau. Specifically, high glucose induces tau
hyper-phosphorylation via glucose-responsive kinases GSK3, PKA, PKC, and CDK5.
This causes dissociation of tau from and subsequent destabilization of
microtubules. Consequently, tau-knockdown in mouse islet β-cells facilitates
microtubule turnover, causing increased basal insulin secretion, depleting
insulin vesicles from the cytoplasm, and impairing GSIS. More importantly,
tau-knockdown uncouples microtubule destabilization from glucose stimulation.
These findings suggest that tau suppresses peripheral microtubules turning-over
to restrict insulin over-secretion at basal conditions and preserve the insulin
pool that can be released in following stimulation; high glucose promotes tau
phosphorylation to enhance microtubule disassembly to acutely enhance GSIS.
Funding
This work was supported by National Institutes of Health (NIH) grant R01-DK106228 (to I.K. and G.G.), DK065949 for GG, R35-GM127098 and R01-GM078373 (to I.K.), and Eli Lilly and Company LIFA fellowship 0101420 (to K. H.).